Cargando…

Chemotherapy-Induced Collagen IV Drives Cancer Cell Motility through Activation of Src and Focal Adhesion Kinase

Triple-negative breast cancer (TNBC) is the most aggressive and deadly subtype of breast cancer, accounting for 30,000 cases annually in the United States. While there are several clinical trials ongoing to identify new agents to treat TNBC, the majority of patients with TNBC are treated with anthra...

Descripción completa

Detalles Bibliográficos
Autores principales: Fatherree, Jackson P., Guarin, Justinne R., McGinn, Rachel A., Naber, Stephen P., Oudin, Madeleine J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381104/
https://www.ncbi.nlm.nih.gov/pubmed/35260882
http://dx.doi.org/10.1158/0008-5472.CAN-21-1823
_version_ 1784769009279827968
author Fatherree, Jackson P.
Guarin, Justinne R.
McGinn, Rachel A.
Naber, Stephen P.
Oudin, Madeleine J.
author_facet Fatherree, Jackson P.
Guarin, Justinne R.
McGinn, Rachel A.
Naber, Stephen P.
Oudin, Madeleine J.
author_sort Fatherree, Jackson P.
collection PubMed
description Triple-negative breast cancer (TNBC) is the most aggressive and deadly subtype of breast cancer, accounting for 30,000 cases annually in the United States. While there are several clinical trials ongoing to identify new agents to treat TNBC, the majority of patients with TNBC are treated with anthracycline- or taxane-based chemotherapies in the neoadjuvant setting, followed by surgical resection and adjuvant chemotherapy. While many patients respond well to this approach, as many as 25% will suffer local or metastatic recurrence within 5 years. Understanding the mechanisms that drive recurrence after chemotherapy treatment is critical to improving survival for patients with TNBC. It is well established that the extracellular matrix (ECM), which provides structure and support to tissues, is a major driver of tumor growth, local invasion, and dissemination of cancer cells to distant metastatic sites. In the present study, we show that decellularized ECM (dECM) obtained from chemotherapy-treated mice increases motility of treatment-naïve breast cancer cells compared with vehicle-treated dECM. Tandem-mass–tag proteomics revealed that anthracycline- and taxane-based chemotherapies induce drug-specific changes in tumor ECM composition. The basement membrane protein collagen IV was significantly upregulated in the ECM of chemotherapy-treated mice and patients treated with neoadjuvant chemotherapy. Collagen IV drove invasion via activation of Src and focal adhesion kinase signaling downstream of integrin α1 and α2, and inhibition of collagen IV–driven signaling decreased motility in chemotherapy-treated dECM. These studies provide a novel mechanism by which chemotherapy may induce metastasis via its effects on ECM composition. SIGNIFICANCE: Cytotoxic chemotherapy induces significant changes in the composition of tumor ECM, inducing a more invasive and aggressive phenotype in residual tumor cells following chemotherapy.
format Online
Article
Text
id pubmed-9381104
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Association for Cancer Research
record_format MEDLINE/PubMed
spelling pubmed-93811042023-01-05 Chemotherapy-Induced Collagen IV Drives Cancer Cell Motility through Activation of Src and Focal Adhesion Kinase Fatherree, Jackson P. Guarin, Justinne R. McGinn, Rachel A. Naber, Stephen P. Oudin, Madeleine J. Cancer Res Convergence and Technologies Triple-negative breast cancer (TNBC) is the most aggressive and deadly subtype of breast cancer, accounting for 30,000 cases annually in the United States. While there are several clinical trials ongoing to identify new agents to treat TNBC, the majority of patients with TNBC are treated with anthracycline- or taxane-based chemotherapies in the neoadjuvant setting, followed by surgical resection and adjuvant chemotherapy. While many patients respond well to this approach, as many as 25% will suffer local or metastatic recurrence within 5 years. Understanding the mechanisms that drive recurrence after chemotherapy treatment is critical to improving survival for patients with TNBC. It is well established that the extracellular matrix (ECM), which provides structure and support to tissues, is a major driver of tumor growth, local invasion, and dissemination of cancer cells to distant metastatic sites. In the present study, we show that decellularized ECM (dECM) obtained from chemotherapy-treated mice increases motility of treatment-naïve breast cancer cells compared with vehicle-treated dECM. Tandem-mass–tag proteomics revealed that anthracycline- and taxane-based chemotherapies induce drug-specific changes in tumor ECM composition. The basement membrane protein collagen IV was significantly upregulated in the ECM of chemotherapy-treated mice and patients treated with neoadjuvant chemotherapy. Collagen IV drove invasion via activation of Src and focal adhesion kinase signaling downstream of integrin α1 and α2, and inhibition of collagen IV–driven signaling decreased motility in chemotherapy-treated dECM. These studies provide a novel mechanism by which chemotherapy may induce metastasis via its effects on ECM composition. SIGNIFICANCE: Cytotoxic chemotherapy induces significant changes in the composition of tumor ECM, inducing a more invasive and aggressive phenotype in residual tumor cells following chemotherapy. American Association for Cancer Research 2022-05-16 2022-03-08 /pmc/articles/PMC9381104/ /pubmed/35260882 http://dx.doi.org/10.1158/0008-5472.CAN-21-1823 Text en ©2022 The Authors; Published by the American Association for Cancer Research https://creativecommons.org/licenses/by-nc-nd/4.0/This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.
spellingShingle Convergence and Technologies
Fatherree, Jackson P.
Guarin, Justinne R.
McGinn, Rachel A.
Naber, Stephen P.
Oudin, Madeleine J.
Chemotherapy-Induced Collagen IV Drives Cancer Cell Motility through Activation of Src and Focal Adhesion Kinase
title Chemotherapy-Induced Collagen IV Drives Cancer Cell Motility through Activation of Src and Focal Adhesion Kinase
title_full Chemotherapy-Induced Collagen IV Drives Cancer Cell Motility through Activation of Src and Focal Adhesion Kinase
title_fullStr Chemotherapy-Induced Collagen IV Drives Cancer Cell Motility through Activation of Src and Focal Adhesion Kinase
title_full_unstemmed Chemotherapy-Induced Collagen IV Drives Cancer Cell Motility through Activation of Src and Focal Adhesion Kinase
title_short Chemotherapy-Induced Collagen IV Drives Cancer Cell Motility through Activation of Src and Focal Adhesion Kinase
title_sort chemotherapy-induced collagen iv drives cancer cell motility through activation of src and focal adhesion kinase
topic Convergence and Technologies
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381104/
https://www.ncbi.nlm.nih.gov/pubmed/35260882
http://dx.doi.org/10.1158/0008-5472.CAN-21-1823
work_keys_str_mv AT fatherreejacksonp chemotherapyinducedcollagenivdrivescancercellmotilitythroughactivationofsrcandfocaladhesionkinase
AT guarinjustinner chemotherapyinducedcollagenivdrivescancercellmotilitythroughactivationofsrcandfocaladhesionkinase
AT mcginnrachela chemotherapyinducedcollagenivdrivescancercellmotilitythroughactivationofsrcandfocaladhesionkinase
AT naberstephenp chemotherapyinducedcollagenivdrivescancercellmotilitythroughactivationofsrcandfocaladhesionkinase
AT oudinmadeleinej chemotherapyinducedcollagenivdrivescancercellmotilitythroughactivationofsrcandfocaladhesionkinase